Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shukuan Li

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Oncotarget|April 14, 2017
Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse modelTakashi Murakami, Shukuan Li, Qinghong Han, et al.
Cancer Letters|January 7, 2018
Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcomaKentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
Chemotherapy|January 24, 2019
Combining Tumor-Selective Bacterial Therapy with Salmonella typhimurium A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft ModelKentaro Miyake, Tasuku Kiyuna, Shukuan Li, et al.
Oncotarget|May 4, 2018
Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse modelKentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
Cell Cycle (Georgetown, Tex.)|January 30, 2018
Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinicKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Biochemical and Biophysical Research Communications|September 1, 2018
Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanomaKei Kawaguchi, Takashi Higuchi, Shukuan Li, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Oncotarget|April 14, 2017
Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse modelTakashi Murakami, Shukuan Li, Qinghong Han, et al.
Cancer Letters|January 7, 2018
Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcomaKentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
Chemotherapy|January 24, 2019
Combining Tumor-Selective Bacterial Therapy with Salmonella typhimurium A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft ModelKentaro Miyake, Tasuku Kiyuna, Shukuan Li, et al.
Oncotarget|May 4, 2018
Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse modelKentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
Cell Cycle (Georgetown, Tex.)|January 30, 2018
Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinicKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Biochemical and Biophysical Research Communications|September 1, 2018
Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanomaKei Kawaguchi, Takashi Higuchi, Shukuan Li, et al.
Pageof 6